Zymfentra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in recombinant enzyme development, improved diagnosis of rare metabolic disorders, availability of orphan drug incentives, expansion of specialty treatment centers, growing patient access programs.

The growth in the forecast period can be attributed to increasing investments in rare disease research, rising demand for long-term enzyme therapies, expansion of homecare treatment models, growing use of digital patient monitoring tools, improved reimbursement frameworks. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare genetic disorders, expansion of personalized treatment approaches, improved biologic manufacturing processes, rising use of home-based infusion therapies.

The rising aging population is expected to drive the growth of the Zymfentra market. An aging population refers to a higher proportion of elderly individuals in society, typically resulting from increased life expectancy and declining birth rates. This demographic shift is creating greater demand for treatments that address age-related conditions. Zymfentra is particularly relevant for the aging population as it provides a convenient and effective treatment for chronic inflammatory diseases, which are more common with advancing age, reducing the need for frequent hospital visits. For instance, in October 2024, according to the World Health Organization, the global population aged 60 years or older is projected to rise from 1 billion in 2020 to 1.4 billion by 2030 and reach 2.1 billion by 2050. Additionally, the population aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million. Therefore, the growing aging population is driving the Zymfentra market.

The increase in healthcare investments is also expected to propel the Zymfentra market. Healthcare investments involve capital allocated to sectors such as pharmaceuticals, biotechnology, medical devices, and healthcare services to advance medical innovation and expand access to care. Rising healthcare investments are driven by increased demand for advanced medical services and innovations due to aging populations and growing health awareness. These investments support the development, regulatory approval, and wider availability of treatments like Zymfentra. For example, in May 2024, according to the Office for National Statistics, a UK-based government agency, the UK’s total healthcare expenditure reached approximately $366 billion (£292 billion), a 5.6% increase from the previous year, with $299 billion (£239 billion) funded by the government. Therefore, rising healthcare investments are supporting the growth of the Zymfentra market.

A key trend in the Zymfentra market is obtaining regulatory approvals to strengthen its competitive position. Drug approval is the process by which authorities evaluate and authorize a new drug for sale and use, ensuring safety, efficacy, and quality based on clinical trial evidence. For instance, in October 2023, Celltrion Inc., a South Korea-based biopharmaceutical company, received U.S. FDA approval for Zymfentra (infliximab-dyyb), a subcutaneous formulation that allows patients to self-administer at home. This reduces the need for frequent hospital visits and the discomfort associated with intravenous infusions. The approval expands treatment options for conditions such as Crohn’s disease, rheumatoid arthritis, and psoriasis, offering faster administration, potential cost savings, and improved patient adherence.

Major companies operating in the zymfentra market are Celltrion Inc.

North America was the largest region in the zymfentra market in 2025. The regions covered in the zymfentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zymfentra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the zymfentra market by increasing costs of imported active pharmaceutical ingredients, biologic manufacturing equipment, sterile packaging materials, and cold-chain logistics systems. North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces increased production and export-related expenses. These tariffs are elevating treatment costs and impacting pricing strategies for specialty therapies. At the same time, they are encouraging localized biologics manufacturing, regional production partnerships, and greater investment in domestic enzyme therapy capabilities.

The zymfentra market research report is one of a series of new reports that provides zymfentra market statistics, including zymfentra industry global market size, regional shares, competitors with a zymfentra market share, detailed zymfentra market segments, market trends and opportunities, and any further data you may need to thrive in the zymfentra industry. This zymfentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zymfentra is a medication used as enzyme replacement therapy (ERT) for patients with certain rare genetic disorders that affect the metabolism of complex sugars. It works by supplying the missing or deficient enzyme, helping to alleviate symptoms and improve quality of life for affected individuals.

The primary indications for Zymfentra include ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. Ulcerative colitis is a chronic inflammatory condition that affects the lining of the large intestine and rectum, causing ulcers and irritation. Zymfentra is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The zymfentra market consists of sales of biosimilars, immunomodulators, monoclonal antibodies and intravenous infusion medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.